TRADES
Latest Trades
85
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 29 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 37,942 0.0141
ARKG 26 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 320,893 0.1195
ARKG 25 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 155,371 0.0605
ARKG 24 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 7,192 0.0029
ARKG 23 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 54,916 0.0209
ARKG 22 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 477,498 0.1790
ARKG 31 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 164,513 0.0488
ARKG 27 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 10,035 0.0031
ARKG 26 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 220,717 0.0673
ARKG 25 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 66,777 0.0205
ARKG 24 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 135,512 0.0394
ARKG 23 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 399,701 0.1196
ARKG 9 May 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 223,407 0.0650
ARKG 30 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 26,361 0.0098
ARKG 29 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 4,021 0.0015
ARKG 28 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 34,412 0.0123
ARKG 25 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 30,000 0.0104
ARKG 24 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 27,500 0.0099
ARKG 23 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 42,500 0.0153
ARKG 22 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 1,974 0.0007
ARKG 21 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 52,752 0.0184
ARKG 15 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 95,474 0.0334
ARKG 14 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 420,216 0.1328
ARKG 11 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 367,391 0.1232
ARKG 10 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 133,254 0.0455
ARKG 7 Mar 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 136,613 0.0450
ARKG 25 Feb 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 48,249 0.0184
ARKG 24 Feb 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 40,000 0.0157
ARKG 23 Feb 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 314,268 0.1164
ARKG 22 Feb 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 362,775 0.1351
ARKG 29 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 29,252 0.0143
ARKG 26 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 14,177 0.0100
ARKG 24 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 61,574 0.0293
ARKG 23 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 615,945 0.2842
ARKG 22 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 127,093 0.0547
ARKG 9 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 43,559 0.0208
ARKG 8 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 41,582 0.0203
ARKG 5 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 239,654 0.1158
ARKG 4 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 986 0.0005
ARKG 3 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 31,397 0.0146
ARKG 2 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 143,500 0.0672
ARKG 1 Nov 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 6,878 0.0034
ARKG 6 Oct 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 103,497 0.0500
ARKG 5 Oct 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 105,175 0.0504
ARKG 10 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 21,332 0.0100
ARKG 9 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 301 0.0000
ARKG 8 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 63,924 0.0300
ARKG 7 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 192,885 0.0900
ARKG 3 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 2,133 0.0000
ARKG 1 Sep 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 800 0.0003
ARKG 31 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 5,886 0.0025
ARKG 30 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 20,540 0.0088
ARKG 27 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 1,000 0.0004
ARKG 26 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 62,252 0.0254
ARKG 25 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 30,596 0.0126
ARKG 24 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 35,080 0.0143
ARKG 10 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 268,463 0.1058
ARKG 9 Aug 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 232,610 0.0923
ARKG 12 May 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 572,104 0.2438
ARKG 11 May 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 30,373 0.0121
ARKG 10 May 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 132,238 0.0525
ARKG 12 Apr 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 179,500 0.0759
ARKG 31 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 700 0.0003
ARKG 30 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 70,147 0.0289
ARKG 29 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 92,300 0.0383
ARKG 26 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 213,550 0.0900
ARKG 25 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 180,617 0.0756
ARKG 24 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 154,223 0.0663
ARKG 10 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 30,323 0.0130
ARKG 9 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 700 0.0000
ARKG 4 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 188,000 0.0931
ARKG 3 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 244,014 0.1219
ARKG 2 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 83,295 0.0413
ARKG 1 Mar 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 21,623 0.0114
ARKG 26 Feb 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 31,636 0.0163
ARKG 25 Feb 2021 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 183,168 0.0949
ARKG 3 Nov 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 21,500 0.0355
ARKG 2 Nov 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 37,220 0.0613
ARKG 22 Oct 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 48,457 0.0790
ARKG 21 Oct 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 11,748 0.0193
ARKG 20 Oct 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 44,254 0.0732
ARKG 6 Oct 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 23,000 0.0460
ARKG 5 Oct 2020 Sell ADPT ADAPTIVE BIOTECHNOLOGIES CORP 56,872 0.1140
ARKG 10 Sep 2020 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 53,865 0.1103
ARKG 9 Sep 2020 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 74,000 0.1458
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.